Suppr超能文献

重组凝血因子VIIa治疗危及生命的咯血。

Recombinant factor VIIa treatment for life-threatening haemoptysis.

作者信息

Yildirim Huseyin, Ucgun Irfan, Yalcin Ahmet Ugur, Gulbaş Zafer, Sahin Garip, Acikalin Mustafa Fuat, Metintas Muzaffer, Ak Guntulu

机构信息

Department of Chest Disease, Osmangazi University, Medical Faculty, 26480 Meselik, Eskisehir, Turkey.

出版信息

Respirology. 2006 Sep;11(5):652-4. doi: 10.1111/j.1440-1843.2006.00906.x.

Abstract

Diffuse alveolar haemorrhage is a severe clinical disorder that may be life-threatening. The early diagnosis of diffuse alveolar haemorrhage and prompt intervention is crucial. Recombinant factor VIIa has been used extensively for the treatment of haemophilia A and B patients. More recently, recombinant factor VIIa has been used successfully for the treatment of bleeding in patients without pre-existing coagulopathy. We describe the successful use of recombinant factor VIIa in a patient with diffuse alveolar haemorrhage secondary to pulmonary-renal syndrome.

摘要

弥漫性肺泡出血是一种可能危及生命的严重临床病症。早期诊断弥漫性肺泡出血并及时干预至关重要。重组凝血因子VIIa已广泛用于治疗甲型和乙型血友病患者。最近,重组凝血因子VIIa已成功用于治疗无既往凝血障碍患者的出血。我们描述了重组凝血因子VIIa在一名继发于肺肾综合征的弥漫性肺泡出血患者中的成功应用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验